Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Berlex Betaseron loses 20% of MS patients to Biogen Avonex -- Schering AG's Vita.

Executive Summary

BERLEX BETASERON LOSES 20% OF PATIENTS TO BIOGEN AVONEX since the introduction of the second interferon beta product in May 1996, Schering AG Chairman Giuseppe Vita said at a press conference in Berlin March 19. He said that as a result of the Avonex launch, "we recorded a decline of 6,000 patients." This "did not surprise us," Vita continued. "A loss of 20% during the transition from a situation as a sole supplier to a competition situation is nearer the lower limit of other experiences."



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts